An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
Latest Information Update: 24 Jun 2020
Price :
$35 *
At a glance
- Drugs EN 145 (Primary)
- Indications Stem cell mobilisation
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Ensoma; Magenta Therapeutics
- 22 Jun 2020 Status changed from active, no longer recruiting to completed.
- 08 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2019 New trial record